THE 30-SECOND OVERVIEW
Tesamorelin dosage research quick start
Tesamorelin is one of the few research peptides with a substantial body of controlled human trial data behind it, which makes the question of what protocols the literature used unusually answerable. This article summarises the dosing used in published tesamorelin research. It is a description of what investigators did, not a protocol recommendation.
Check the formulation
Tesamorelin 10 mg vial. Other formats and blends may have different strengths.
Amount ≠ schedule
Concentration arithmetic does not determine dosing frequency or a safe human daily amount.
LABORATORY CONCENTRATION MATH
Tesamorelin dosage calculator
Calculate the amount in a laboratory sample of the 10 mg Tesamorelin vial. Enter the final solution volume, not the container capacity.
Enter positive volumes; the sample cannot exceed the final solution volume.
Illustrative arithmetic only. These inputs are not recommended preparation volumes or doses. This calculator does not recommend a route or schedule for human use.
What Tesamorelin Is
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is a 44-amino-acid peptide with a trans-3-hexenoyl group attached at the N-terminus, a modification that slows enzymatic degradation and extends its half-life relative to native GHRH.
Mechanistically it binds GHRH receptors on the anterior pituitary and stimulates endogenous growth hormone release. This matters for interpreting the literature: tesamorelin acts upstream, prompting the body's own pulsatile GH secretion, rather than supplying exogenous growth hormone directly. Studies consequently report changes in IGF-1 as the downstream marker rather than measuring the peptide's effect in isolation.
Tesamorelin has been evaluated in registered clinical trials and holds regulatory approval in the United States under the brand name Egrifta for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. That regulatory history is why its dosing literature is more consistent than that of most research peptides.
The Dosing Used in Published Research
Across the pivotal trials, the protocol is remarkably uniform: 2mg administered once daily by subcutaneous injection.
Two phase 3 trials enrolling over 800 participants both used 2mg daily subcutaneously for 26 weeks, with an extension phase to 52 weeks. Participants who continued on tesamorelin through the extension maintained the changes observed at 26 weeks; those switched to placebo did not, indicating the effect was dependent on continued administration.
The consistency of the 2mg figure across independent trials is the single most useful fact in the tesamorelin dosing literature. Where most research peptides have a scattered range assembled from small studies, tesamorelin has convergent protocols from adequately powered trials.
Why 2mg, and Why Once Daily
The once-daily timing follows from the mechanism. GHRH analogues work by amplifying the body's own secretory pulses, and growth hormone release is naturally concentrated in the hours after sleep onset. Trials administered tesamorelin in the evening for that reason.
The 2mg figure came out of earlier dose-ranging work rather than being chosen arbitrarily. Investigators evaluated 1mg and 2mg daily against placebo, and the 2mg arm produced the clearer IGF-1 response, which carried forward into the phase 3 design.
It is worth noting what that means and does not mean. The 2mg protocol was optimised for a specific clinical population and a specific measured endpoint over 26 weeks. It is the dose that trial designers selected for that question, not a universal figure.
Reconstitution and Handling
Tesamorelin is supplied lyophilised and requires reconstitution before use. The trial protocols reconstituted with sterile diluent immediately prior to administration, and this is one of the more consequential handling details in the literature: tesamorelin is comparatively unstable in solution.
Reconstituted tesamorelin degrades meaningfully faster than many research peptides, and published stability data supports preparing it fresh rather than storing a reconstituted vial for extended periods. Lyophilised material is stable under refrigeration; the solution is where the sensitivity lies.
Practical points that recur in handling guidance: introduce diluent slowly against the vial wall rather than directly onto the powder, swirl rather than shake, and keep the reconstituted solution cold and protected from light. Vigorous agitation can denature peptides in solution, and tesamorelin's size makes it more susceptible than a short tripeptide would be.
Concentration follows from the volume of diluent added, and this is where errors typically enter. Reconstituting the same quantity of peptide in 1mL versus 2mL produces solutions differing twofold in concentration, so the volume drawn for a given quantity changes accordingly. Any protocol carried over from a differently reconstituted vial without recalculating will be off. Our peptide calculator handles the conversion.
What the Research Does Not Establish
Several limits are worth stating explicitly, because they are routinely elided in secondary write-ups.
The trial population was specific (adults with HIV-associated lipodystrophy) and results in that group do not automatically generalise. Extrapolating from a studied population to an unstudied one is an assumption, not a finding.
Effects were dependent on continued administration. The extension-phase data showed that participants who stopped did not maintain the changes, which is a meaningful constraint on how the results should be read.
IGF-1 elevation is the expected pharmacodynamic consequence of GHRH agonism, and trials monitored it. Studies included monitoring for a reason, and the literature reflects a population under clinical supervision rather than unmonitored use.
Comparison With Other GHRH Analogues
Tesamorelin is frequently compared with CJC-1295 and sermorelin, which share the GHRH-agonist mechanism but differ substantially in evidence base.
Sermorelin is a shorter GHRH fragment with a much briefer half-life. CJC-1295 exists in two forms (with and without the DAC modification) whose half-lives differ by orders of magnitude, and neither has a trial record approaching tesamorelin's.
The practical distinction for a researcher is evidence density rather than mechanism. Tesamorelin's protocols come from adequately powered controlled trials; the others rest largely on smaller studies and pharmacokinetic work. If protocol confidence is what matters to a research question, that difference is the relevant one.
The Takeaway
The published tesamorelin literature converges on 2mg once daily by subcutaneous injection, administered in the evening, in a defined clinical population over 26 to 52 weeks. That consistency across independent adequately powered trials is unusual among research peptides and is the main reason tesamorelin's dosing literature is worth reading closely.
Both the 10mg vial and the tesamorelin nasal spray are supplied lyophilised. The handling detail that matters most is stability in solution: tesamorelin is less forgiving than most peptides once reconstituted, and concentration errors from inconsistent reconstitution volumes are the common failure mode. Purity and identity for each lot are in our lab results.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Falutz, J., Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370.
2. Falutz, J., Mamputu, J. C., Potvin, D., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. Journal of Clinical Endocrinology and Metabolism, 95(9), 4291-4304.
3. Stanley, T. L., Falutz, J., Marsolais, C., et al. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 54(11), 1642-1651.
